Export

Adalimumab
Essential medicine status
General description

INN
Adalimumab
Medicine type
Biological agent
EML status history
First added in 2019 (TRS 1021) for Axial spondyloarthritis
Added in 2019 (TRS 1021) for Rheumatoid arthritis
Added in 2019 (TRS 1021) for Crohn disease site
Therapeutic equivalent for
Wikipedia
DrugBank
Recommendations
Section
Immunomodulators for non-malignant disease
  • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL